These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Anakinra therapy in a child with systemic-onset juvenile rheumatoid arthritis after human herpesvirus 6 encephalitis. Mirkinson LJ; Nagle D; Kadom N; Jones OY J Clin Rheumatol; 2006 Apr; 12(2):83-6. PubMed ID: 16601542 [TBL] [Abstract][Full Text] [Related]
4. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Lequerré T; Quartier P; Rosellini D; Alaoui F; De Bandt M; Mejjad O; Kone-Paut I; Michel M; Dernis E; Khellaf M; Limal N; Job-Deslandre C; Fautrel B; Le Loët X; Sibilia J; ; Ann Rheum Dis; 2008 Mar; 67(3):302-8. PubMed ID: 17947302 [TBL] [Abstract][Full Text] [Related]
5. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Lovell DJ; Bowyer SL; Solinger AM Arthritis Rheum; 2005 Apr; 52(4):1283-6. PubMed ID: 15818707 [TBL] [Abstract][Full Text] [Related]
6. Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis. Tesser J; Fleischmann R; Dore R; Bennett R; Solinger A; Joh T; Modafferi D; Schechtman J; J Rheumatol; 2004 Apr; 31(4):649-54. PubMed ID: 15088288 [TBL] [Abstract][Full Text] [Related]
7. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis. Furst DE Clin Ther; 2004 Dec; 26(12):1960-75. PubMed ID: 15823761 [TBL] [Abstract][Full Text] [Related]
9. Bringing the clinical experience with anakinra to the patient. Cohen SB; Rubbert A Rheumatology (Oxford); 2003 May; 42 Suppl 2():ii36-40. PubMed ID: 12817094 [TBL] [Abstract][Full Text] [Related]
10. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Fitzgerald AA; Leclercq SA; Yan A; Homik JE; Dinarello CA Arthritis Rheum; 2005 Jun; 52(6):1794-803. PubMed ID: 15934079 [TBL] [Abstract][Full Text] [Related]
11. The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis. Cohen SB Rheum Dis Clin North Am; 2004 May; 30(2):365-80, vii. PubMed ID: 15172046 [TBL] [Abstract][Full Text] [Related]
12. [Interleukin-1 receptor antagonists in the treatment rheumatoid arthritis]. Zoń-Giebel A; Kotulska A; Giebel S; Cader SA; Kucharz EJ Przegl Lek; 2002; 59(11):916-8. PubMed ID: 12715722 [TBL] [Abstract][Full Text] [Related]
13. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ostendorf B; Iking-Konert C; Kurz K; Jung G; Sander O; Schneider M Ann Rheum Dis; 2005 Apr; 64(4):630-3. PubMed ID: 15345502 [TBL] [Abstract][Full Text] [Related]
14. Anakinra treatment for systemic juvenile idiopathic arthritis and adult onset Still disease. Woo P Ann Rheum Dis; 2008 Mar; 67(3):281-2. PubMed ID: 18292104 [No Abstract] [Full Text] [Related]
15. The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis. Swart JF; Barug D; Möhlmann M; Wulffraat NM Expert Opin Biol Ther; 2010 Dec; 10(12):1743-52. PubMed ID: 20979564 [TBL] [Abstract][Full Text] [Related]
16. [Interleukin-1 receptor antagonist anakinra (Kineret) for treatment of rheumatic arthritis]. Rubbert-Roth A; Perniok A Z Rheumatol; 2003 Aug; 62(4):367-77. PubMed ID: 12928941 [TBL] [Abstract][Full Text] [Related]
17. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Nigrovic PA; Mannion M; Prince FH; Zeft A; Rabinovich CE; van Rossum MA; Cortis E; Pardeo M; Miettunen PM; Janow G; Birmingham J; Eggebeen A; Janssen E; Shulman AI; Son MB; Hong S; Jones K; Ilowite NT; Cron RQ; Higgins GC Arthritis Rheum; 2011 Feb; 63(2):545-55. PubMed ID: 21280009 [TBL] [Abstract][Full Text] [Related]